The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Sohlberg E, Malmberg KJ(2025) The innate power of natural killer cells in cancer therapy Nat Med(in press) DOI 10.1038/s41591-025-03712-9, PubMed 40355615
Trachsel-Moncho L, Mathai BJ, Veroni C, Simonsen A(2025) SNX10 at the crossroad of endocytosis and piecemeal mitophagy Autophagy, 1-3(in press) DOI 10.1080/15548627.2025.2499641, PubMed 40327657
Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK(2025) Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50 ESMO Open, 10(5), 105073(in press) DOI 10.1016/j.esmoop.2025.105073, PubMed 40305908
Yin Y, Xu H, He L, Brown JR, Mato AR, Aittokallio T, Skånland SS(2025) Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia Clin Cancer Res, 31(10), 1943-1955 DOI 10.1158/1078-0432.CCR-24-2911, PubMed 40085050
Sohlberg E, Malmberg KJ(2025) The innate power of natural killer cells in cancer therapy Nat Med(in press) DOI 10.1038/s41591-025-03712-9, PubMed 40355615
Garcia-Foncillas J, Bayle A, Arnold D, Avouac B, Awada A, de la Cruz-Merino L, Helland Å, Lassen U, Laurent-Puig P, Normanno N, Rohrberg K, Taieb J, Stenzinger A(2025) Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access Future Oncol, 1-8(in press) DOI 10.1080/14796694.2025.2501523, PubMed 40340714